PEDIATRICS Vol. 100 No. 6 December 1997, pp. 937-942
Respiratory Syncytial Virus Immune Globulin Treatment of RSV Lower Respiratory Tract Infection in Previously Healthy Children
Received Sep 17, 1996; accepted May 13, 1997.
,
,
From the * Children's Hospital National Medical Center,
Washington, DC; Vanderbilt University Children's Hospital,
Nashville, Tennessee; § the Children's Hospital, Denver, Colorado;
West Virginia University Health Science Center, Morgantown, West
Virginia; ¶ Albany Medical College, Albany, New York; # MedImmune Inc,
Gaithersburg, Maryland; and ** Uniformed Services University of Health
Sciences, Bethesda, Maryland.
Objective. To evaluate the efficacy of high titer respiratory syncytial virus (RSV) immune globulin (RSVIG) in the treatment of previously healthy children hospitalized with proven RSV lower tract infection (LRI).
Method. Infants and young children 
2 years of age with
RSV LRI of 4 days duration, and respiratory scores 
2.5 were
enrolled.
Results. One hundred and one previously healthy children
hospitalized with RSV LRI received either 1500 mg/kg of RSVIG
(RespiGam, MedImmune Inc, Gaithersburg, MD) or albumin placebo in a
randomized, double-blind, placebo-controlled trial. Forty-six RSVIG and
52 recipients of placebo met all eligibility criteria. Demographic characteristics of the two groups were similar. More RSVIG recipients (46% vs 29%) had an SaO2 85% at entry than did placebo
recipients, but a higher proportion of placebo recipients required
intensive care unit (ICU) care and mechanical ventilation at study
entry. The mean RSV hospital stay was 5.52 ± 0.69 days (SE) for
placebo and 4.58 ± 0.40 days for RSVIG. Additionally, there was
an interaction between treatment group and entry respiratory score,
which led to subgroup analysis. Children with modest respiratory
illness did not receive any benefit from RSVIG therapy. RSVIG
recipients with more severe illness (entry respiratory scores 3.0)
had 1.6 fewer hospital days and 2.7 days less ICU stays.
Conclusion. RSVIG infusions seemed safe and generally well tolerated. Although some beneficial effect trends were seen for those with more severe disease who were treated there was no evidence that treatment with RSVIG resulted in reduced hospitalization and reduced ICU stays in all children with RSV disease.
Key words: respiratory syncytial virus, bronchiolitis, lower respiratory tract infections, respiratory syncytial virus immune globulin, randomized, controlled trial.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Y. Richardson, M. G. Ottolini, L. Pletneva, M. Boukhvalova, S. Zhang, S. N. Vogel, G. A. Prince, and J. C. G. Blanco Respiratory Syncytial Virus (RSV) Infection Induces Cyclooxygenase 2: A Potential Target for RSV Therapy J. Immunol., April 1, 2005; 174(7): 4356 - 4364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Easton, J. B. Domachowske, and H. F. Rosenberg Animal Pneumoviruses: Molecular Genetics and Pathogenesis Clin. Microbiol. Rev., April 1, 2004; 17(2): 390 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Bordley, M. Viswanathan, V. J. King, S. F. Sutton, A. M. Jackman, L. Sterling, and K. N. Lohr Diagnosis and Testing in Bronchiolitis: A Systematic Review Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. King, M. Viswanathan, W. C. Bordley, A. M. Jackman, S. F. Sutton, K. N. Lohr, and T. S. Carey Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 127 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Randolph, K. L. Meert, M. E. O'Neil, J. H. Hanson, P. M. Luckett, J. H. Arnold, R. G. Gedeit, P. N. Cox, J. S. Roberts, S. T. Venkataraman, et al. The Feasibility of Conducting Clinical Trials in Infants and Children with Acute Respiratory Failure Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1334 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. I. Shireman and K. S. Braman Impact and Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis for Kansas Medicaid's High-Risk Children Arch Pediatr Adolesc Med, December 1, 2002; 156(12): 1251 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Ottolini, S. J. Curtis, D. D. Porter, A. Mathews, J. Y. Richardson, V. G. Hemming, and G. A. Prince Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2299 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Hemming Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases Clin. Vaccine Immunol., September 1, 2001; 8(5): 859 - 863. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Nasr, P. J. Strouse, E. Soskolne, N. J. Maxvold, K. A. Garver, B. K. Rubin, and F. W. Moler Efficacy of Recombinant Human Deoxyribonuclease I in the Hospital Management of Respiratory Syncytial Virus Bronchiolitis Chest, July 1, 2001; 120(1): 203 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Hall Respiratory Syncytial Virus and Parainfluenza Virus N. Engl. J. Med., June 21, 2001; 344(25): 1917 - 1928. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Keller and E. R. Stiehm Passive Immunity in Prevention and Treatment of Infectious Diseases Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Swingler, G. D. Hussey, and M. Zwarenstein Duration of Illness in Ambulatory Children Diagnosed With Bronchiolitis Arch Pediatr Adolesc Med, October 1, 2000; 154(10): 997 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Uzel, A. Premkumar, H. L. Malech, and S. M. Holland Respiratory Syncytial Virus Infection in Patients With Phagocyte Defects Pediatrics, October 1, 2000; 106(4): 835 - 837. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. Garrison, D. A. Christakis, E. Harvey, P. Cummings, and R. L. Davis Systemic Corticosteroids in Infant Bronchiolitis: A Meta-analysis Pediatrics, April 1, 2000; 105(4): 44e - 44. [Abstract] [Full Text]
|
|
|
|
|
|
R. Weltzin and T. P. Monath Intranasal Antibody Prophylaxis for Protection against Viral Disease Clin. Microbiol. Rev., July 1, 1999; 12(3): 383 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 New Immune Globulin for Treatment of RSV Journal Watch Infectious Diseases, February 1, 1998; 1998(201): 14 - 14. [Full Text]
|
|
